Gene expression profile of ADAMs and ADAMTSs metalloproteinases in normal and malignant plasma cells and in the bone marrow environment

Experimental Hematology

Volumn 39, Issue 5, 2011, Pages

  Bret, Caroline ^a,b,c   Hose, Dirk ^d,e   Reme, Thierry ^a,b   Kassambara, Alboukadel ^a,b   Seckinger, Anja ^d   Meißner, Tobias ^d   Schved, Jean Franois ^b,c   Kanouni, Tarik ^b   Goldschmidt, Hartmut ^d   Klein, Bernard ^a,b,c  

^a INSERM   (France)

^b MONTPELLIER UNIVERSITY HOSPITAL   (France)

^c UNIV MONTPELLIER   (France)

^d Medizinische Klinik und Poliklinik V   (Germany)

^e Nationales Centrum fur Tumorerkrankungen   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADAM PROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE;

ADAM GENE; ADAM10 GENE; ADAM19 GENE; ADAM23 GENE; ADAM28 GENE; ADAMTS GENE; ADAMTS6 GENE; ADAMTS9 GENE; ARTICLE; BONE MARROW CELL; CONTROLLED STUDY; GENE; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MEMORY CELL; MULTIPLE MYELOMA; MYELOMA CELL; PLASMA CELL; PRIORITY JOURNAL; PROGNOSIS; STROMA CELL; TIMP1 GENE; TIMP2 GENE;

EID: 79955146210     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2011.02.002     Document Type: Article

References (68)

1. Edwards D.R., Handsley M.M., Pennington C.J. The ADAM metalloproteinases. Mol Aspects Med 2008, 29:258-289.
2. Porter S., Clark I.M., Kevorkian L., Edwards D.R. The ADAMTS metalloproteinases. Biochem J 2005, 15:15-27.
3. Arribas J., Bech-Serra J.J., Santiago-Josefat B. ADAMs, cell migration and cancer. Cancer Metastasis Rev 2006, 25:57-68.
4. Murphy G. The ADAMs: signalling scissors in the tumour microenvironment. Nat Rev Cancer 2008, 8:929-941.
5. Porter S., Scott S.D., Sassoon E.M., et al. Dysregulated expression of adamalysin-thrombospondin genes in human breast carcinoma. Clin Cancer Res 2004, 10:2429-2440.
6. Dunn J.R., Reed J.E., du Plessis D.G., et al. Expression of ADAMTS-8, a secreted protease with antiangiogenic properties, is downregulated in brain tumours. Br J Cancer 2006, 94:1186-1193.
7. Cross N.A., Chandrasekharan S., Jokonya N., et al. The expression and regulation of ADAMTS-1, -4, -5, -9, and -15, and TIMP-3 by TGFbetal in prostate cells: relevance to the accumulation of versican. Prostate 2005, 63:269-275.
8. Rocks N., Paulissen G., Quesada-Calvo F., et al. ADAMTS-1 metalloproteinase promotes tumor development through the induction of a stromal reaction in vivo. Cancer Res 2008, 68:9541-9550.
9. Llamazares M., Obaya A.J., Moncada-Pazos A., et al. The ADAMTS12 metalloproteinase exhibits anti-tumorigenic properties through modulation of the Ras-dependent ERK signalling pathway. J Cell Sci 2007, 120(Pt 20):3544-3552.
10. Sprynski A.C., Hose D., Caillot L., et al. The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor. Blood 2009, 113:4614-4626.
11. Hose D., Moreaux J., Meissner T., et al. Induction of angiogenesis by normal and malignant plasma cells. Blood 2009, 114:128-143.
12. McKie N., Dallas D.J., Edwards T., Apperley J.F., Russell R.G., Croucher P.I. Cloning of a novel membrane-linked metalloproteinase from human myeloma cells. Biochem J 1996, 318:459-462.
13. Wu E., Croucher P.I., McKie N. Expression of members of the novel membrane linked metalloproteinase family ADAM in cells derived from a range of haematological malignancies. Biochem Biophys Res Commun 1997, 235:437-442.
14. Atanackovic D., Arfsten J., Cao Y., et al. Cancer-testis antigens are commonly expressed in multiple myeloma and induce systemic immunity following allogeneic stem cell transplantation. Blood 2007, 109:1103-1112.
15. Karadag A., Zhou M., Croucher P.I. ADAM-9 (MDC-9/meltrin-gamma), a member of the a disintegrin and metalloproteinase family, regulates myeloma-cell-induced interleukin-6 production in osteoblasts by direct interaction with the alpha(v)beta5 integrin. Blood 2006, 107:3271-3278.
16. Brito J.L., Walker B., Jenner M., et al. MMSET deregulation affects cell cycle progression and adhesion regulons in t(4;14) myeloma plasma cells. Haematologica 2009, 94:78-86.
17. Guedez L., Martinez A., Zhao S., et al. Tissue inhibitor of metalloproteinase 1 (TIMP-1) promotes plasmablastic differentiation of a Burkitt lymphoma cell line: implications in the pathogenesis of plasmacytic/plasmablastic tumors. Blood 2005, 105:1660-1668.
18. Zdzisinska B., Walter-Croneck A., Kandefer-Szerszen M. Matrix metalloproteinases-1 and -2, and tissue inhibitor of metalloproteinase-2 production is abnormal in bone marrow stromal cells of multiple myeloma patients. Leuk Res 2008, 32:1763-1769.
19. Hargreaves P.G., Wang F., Antcliff J., et al. Human myeloma cells shed the interleukin-6 receptor: inhibition by tissue inhibitor of metalloproteinase-3 and a hydroxamate-based metalloproteinase inhibitor. Br J Haematol 1998, 101:694-702.
20. Zhang X.G., Gaillard J.P., Robillard N., et al. Reproducible obtaining of human myeloma cell lines as a model for tumor stem cell study in human multiple myeloma. Blood 1994, 83:3654-3663.
21. Rebouissou C., Wijdenes J., Autissier P., et al. A gp130 interleukin-6 transducer-dependent SCID model of human multiple myeloma. Blood 1998, 91. 4727-4237.
22. Tarte K., Zhang X.G., Legouffe E., et al. Induced expression of B7-1 on myeloma cells following retroviral gene transfer results in tumor-specific recognition by cytotoxic T cells. J Immunol 1999, 163:514-524.
23. Gu Z.J., Vos J.D., Rebouissou C., et al. Agonist anti-gp130 transducer monoclonal antibodies are human myeloma cell survival and growth factors. Leukemia 2000, 14:188-197.
24. Moreaux J., Klein B., Bataille R., et al. A high-risk signature for patients with multiple myeloma established from human myeloma cell lines molecular classification. Haematologica 2010 Dec 29, [Epub ahead of print].
25. Mahtouk K., Hose D., Reme T., et al. Expression of EGF-family receptors and amphiregulin in multiple myeloma. Amphiregulin is a growth factor for myeloma cells. Oncogene 2005, 24:3512-3524.
26. Jourdan M., Caraux A., De Vos J., et al. An in vitro model of differentiation of memory B cells into plasmablasts and plasma cells including detailed phenotypic and molecular characterization. Blood 2009, 114:5173-5181.
27. Tarte K., De Vos J., Thykjaer T., et al. Generation of polyclonal plasmablasts from peripheral blood B cells: a normal counterpart of malignant plasmablasts. Blood 2002, 100:1113-1122.
28. Goldschmidt H., Egerer G., Ho A.D. Autologous and allogeneic stem cell transplantation in multiple myeloma. Bone Marrow Transplant 2000, 25(suppl 2):S25-S26.
29. Durie B.G., Salmon S.E. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975, 36:842-854.
30. Barlogie B., Tricot G., Rasmussen E., et al. Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies. Blood 2006, 107:2633-2638.
31. Corre J., Mahtouk K., Attal M., et al. Bone marrow mesenchymal stem cells are abnormal in multiple myeloma. Leukemia 2007, 21:1079-1088.
32. Moreaux J., Cremer F.W., Reme T., et al. The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature. Blood 2005, 106:1021-1030.
33. Moreaux J., Hose D., Kassambara A., et al. Osteoclast-gene expression profiling reveals osteoclast-derived CCR2-chemokines promoting myeloma cell migration. Blood 2011, 117:1280-1290.
34. De Vos J., Thykjaer T., Tarte K., et al. Comparison of gene expression profiling between malignant and normal plasma cells with oligonucleotide arrays. Oncogene 2002, 21:6848-6857.
35. Reme T., Hose D., De Vos J., et al. A new method for class prediction based on signed-rank algorithms applied to Affymetrix microarray experiments. BMC Bioinformatics 2008, 9:16.
36. Assou S., Le Carrour T., Tondeur S., et al. A meta-analysis of human embryonic stem cells transcriptome integrated into a web-based expression atlas. Stem Cells 2007, 25:961-973.
37. Turner S.L., Blair-Zajdel M.E., Bunning R.A. ADAMs and ADAMTSs in cancer. Br J Biomed Sci 2009, 66:117-128.
38. Roberts C.M., Tani P.H., Bridges L.C., Laszik Z., Bowditch R.D. MDC-L, a novel metalloprotease disintegrin cysteine-rich protein family member expressed by human lymphocytes. J Biol Chem 1999, 274:29251-29259.
39. Reiss K., Maretzky T., Ludwig A., et al. ADAM10 cleavage of N-cadherin and regulation of cell-cell adhesion and beta-catenin nuclear signalling. EMBO J 2005, 24:742-752.
40. Anderegg U., Eichenberg T., Parthaune T., et al. ADAM10 is the constitutive functional sheddase of CD44 in human melanoma cells. J Invest Dermatol 2009, 129:1471-1482.
41. Hartmann D., de Strooper B., Serneels L., et al. The disintegrin/metalloprotease ADAM 10 is essential for Notch signalling but not for alpha-secretase activity in fibroblasts. Hum Mol Genet 2002, 11:2615-2624.
42. Six E., Ndiaye D., Laabi Y., et al. The Notch ligand Delta1 is sequentially cleaved by an ADAM protease and gamma-secretase. Proc Natl Acad Sci U S A 2003, 100:7638-7643.
43. Sahin U., Weskamp G., Kelly K., et al. Distinct roles for ADAM10 and ADAM17 in ectodomain shedding of six EGFR ligands. J Cell Biol 2004, 164:769-779.
44. Zhou H.M., Weskamp G., Chesneau V., et al. Essential role for ADAM19 in cardiovascular morphogenesis. Mol Cell Biol 2004, 24:96-104.
45. Yumoto N., Wakatsuki S., Kurisaki T., et al. Meltrin beta/ADAM19 interacting with EphA4 in developing neural cells participates in formation of the neuromuscular junction. PLoS One 2008, 3:e3322.
46. Zheng Y., Saftig P., Hartmann D., Blobel C. Evaluation of the contribution of different ADAMs to tumor necrosis factor alpha (TNFalpha) shedding and of the function of the TNFalpha ectodomain in ensuring selective stimulated shedding by the TNFalpha convertase (TACE/ADAM17). J Biol Chem 2004, 279:42898-42906.
47. Brew K., Dinakarpandian D., Nagase H. Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta 2000, 1477:267-283.
48. Baker A.H., Edwards D.R., Murphy G. Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J Cell Sci 2002, 115:3719-3727.
49. Bertaux B., Hornebeck W., Eisen A.Z., Dubertret L. Growth stimulation of human keratinocytes by tissue inhibitor of metalloproteinases. J Invest Dermatol 1991, 97:679-685.
50. Stetler-Stevenson W.G., Bersch N., Golde D.W. Tissue inhibitor of metalloproteinase-2 (TIMP-2) has erythroid-potentiating activity. FEBS Lett 1992, 296:231-234.
51. Hayakawa T., Yamashita K., Ohuchi E., Shinagawa A. Cell growth-promoting activity of tissue inhibitor of metalloproteinases-2 (TIMP-2). J Cell Sci 1994, 107:2373-2379.
52. Nemeth J.A., Rafe A., Steiner M., Goolsby C.L. TIMP-2 growth-stimulatory activity: a concentration- and cell type-specific response in the presence of insulin. Exp Cell Res 1996, 224:110-115.
53. Roy R., Zhang B., Moses M.A. Making the cut: protease-mediated regulation of angiogenesis. Exp Cell Res 2006, 312:608-622.
54. Costa F.F., Verbisck N.V., Salim A.C., et al. Epigenetic silencing of the adhesion molecule ADAM23 is highly frequent in breast tumors. Oncogene 2004, 23:1481-1488.
55. Hagihara A., Miyamoto K., Furuta J., et al. Identification of 27 5 CpG islands aberrantly methylated and 13 genes silenced in human pancreatic cancers. Oncogene 2004, 23:8705-8710.
56. Takada H., Imoto I., Tsuda H., et al. ADAM23, a possible tumor suppressor gene, is frequently silenced in gastric cancers by homozygous deletion or aberrant promoter hypermethylation. Oncogene 2005, 24:8051-8060.
57. Choi J.S., Kim K.H., Jeon Y.K., et al. Promoter hypermethylation of the ADAM23 gene in colorectal cancer cell lines and cancer tissues. Int J Cancer 2009, 124:1258-1262.
58. Cal S., Freije J.M., Lopez J.M., Takada Y., Lopez-Otin C. ADAM 23/MDC3, a human disintegrin that promotes cell adhesion via interaction with the alphavbeta3 integrin through an RGD-independent mechanism. Mol Biol Cell 2000, 11:1457-1469.
59. Lo P.H., Leung A.C., Kwok C.Y., et al. Identification of a tumor suppressive critical region mapping to 3p14.2 in esophageal squamous cell carcinoma and studies of a candidate tumor suppressor gene, ADAMTS9. Oncogene 2007, 26:148-157.
60. Lung H.L., Lo P.H., Xie D., et al. Characterization of a novel epigenetically-silenced, growth-suppressive gene, ADAMTS9, and its association with lymph node metastases in nasopharyngeal carcinoma. Int J Cancer 2008, 123:401-408.
61. Liu H., Shim A.H., He X. Structural characterization of the ectodomain of a disintegrin and metalloproteinase-22 (ADAM22), a neural adhesion receptor instead of metalloproteinase: Insights on ADAM function. J Biol Chem 2009, 284:29077-29086.
62. Zhu P., Sun Y., Xu R., et al. The interaction between ADAM 22 and 14-3-3zeta: regulation of cell adhesion and spreading. Biochem Biophys Res Commun 2003, 301:991-999.
63. DAbaco G.M., Ng K., Paradiso L., Godde N.J., Kaye A., Novak U. ADAM22, expressed in normal brain but not in high-grade gliomas, inhibits cellular proliferation via the disintegrin domain. Neurosurgery 2006, 58:179-186. discussion 186.
64. Verrier S., Hogan A., McKie N., Horton M. ADAM gene expression and regulation during human osteoclast formation. Bone 2004, 35:34-46.
65. Mochizuki S., Shimoda M., Shiomi T., Fujii Y., Okada Y. ADAM28 is activated by MMP-7 (matrilysin-1) and cleaves insulin-like growth factor binding protein-3. Biochem Biophys Res Commun 2004, 315:79-84.
66. Mitsui Y., Mochizuki S., Kodama T., et al. ADAM28 is overexpressed in human breast carcinomas: implications for carcinoma cell proliferation through cleavage of insulin-like growth factor binding protein-3. Cancer Res 2006, 66:9913-9920.
67. Bates E.E., Fridman W.H., Mueller C.G. The ADAMDEC1 (decysin) gene structure: evolution by duplication in a metalloprotease gene cluster on chromosome 8p12. Immunogenetics 2002, 54:96-105.
68. Clark J.C., Thomas D.M., Choong P.F., Dass C.R. RECK-a newly discovered inhibitor of metastasis with prognostic significance in multiple forms of cancer. Cancer Metastasis Rev 2007, 26:675-683.